Webcasting is the most cost-effective way for a single user or a group to view LIVE or archived meetings.
By using internet streaming technology we broadcast from the FDA meeting right to your desktop, to unlimited locations, worldwide. Our cameras focus in on the committee, the presenters and their presentations while sending video and audio live to your desktop. We offer single viewer and group options. If you would like to broadcast a meeting to your group - purchase a multi-viewer "group" license and simply hook up your PC to the internet and project your image on a projector screen while amplifying your audio signal in your conference room.
Stream Quality: Very Good
Dependability: Very Good
Single viewer license (per person - per pc): Allows for a single viewer to view the webcast on their desktop. Cost: $140 - $250
Multi viewer Group license (per person - per pc): Allows for a fullscreen viewing for meeting rooms, auditoriums. Cost: $800 - $1,200
Windows PC or MAC with Sound Card/Speakers, Windows Media Player 7 or above and A Broadband Internet Connection.
- Bone, Reproductive and Urologic Drugs Advisory Committee
Meeting Date: 12/6/16-12/6/16
The committee will discuss appropriate clinical trial design features, including acceptable endpoints for demonstrating clinical benefit, for drugs intended to treat secondary hypogonadism while preserving or improving testicular function, including spermatogenesis.
|Location:||Tommy Douglas Conference Center||Related News Links:||Not Available|
- Blood Products Advisory Committee Meeting
Meeting Date: 11/17/16-11/18/16
On the morning of November 17, 2016, the Committee will meet in open session to discuss strategies to manage iron deficiency associated with blood donation. The Committee will also discuss proposed procedures for assuring donor safety for collections of blood from female donors with hemoglobin values of 12.0-12.4g/dL or a hematocrit value between 36 and 38. In the afternoon, the Committee will meet in open session to discuss adverse reactions related to blood donation in teenage (16 to 18 years) donors, and the effectiveness of several mitigation measures. On November 18, 2016, the Committee will meet in open session to hear an informational session on Zika virus and blood safety in the United States. Following the informational session, the Committee will hear presentations on the following topics: (1) The Transfusion Transmissible Infections Monitoring System; (2) a summary of the FDA workshop on new methods to predict the immunogenicity of therapeutic coagulation proteins; and (3) a summary of the FDA workshop on preclinical evaluation of red blood cells for transfusion.
|Location:||FDA White Oak||Related News Links:||Not Available|
- Microbiology Devices Panel of the Medical Devices Advisory Committee
Meeting Date: 11/9/16-11/10/16
On November 9, 2016, during session one, the committee will discuss and make recommendations regarding the reclassification of quantitative Cytomegalovirus (CMV) viral load devices from class III (Premarket approval) to class II (510(k)). A nucleic acid-based in vitro diagnostic device for the quantitation of CMV viral load, within the context of transplant patient management, is a post-amendment device classified into class III under section 513(f)(1) of the Federal Food, Drug, and Cosmetic Act (the FD&C Act )(21 U.S.C. 360c(f)(1). To date, the following product code has been established for CMV viral load devices: PAB (CMV DNA Quantitative Assay). During session two, the committee will discuss and make recommendations regarding the appropriate initial classification for qualitative or quantitative viral load devices for Epstein-Barr virus, BK virus, JC virus, Human Herpesvirus 6, and Adenovirus infections. FDA is seeking expert recommendations to assess the potential risks and benefits of these devices when used in patients following solid-organ or stem cell transplantation.
|Location:||Gaithersburg Holiday Inn||Related News Links:||Not Available|
- Meeting of the Antimicrobial Drugs Advisory Committee
Meeting Date: 11/4/16-11/4/16
The committee will discuss new drug applications 209006 and 209007, solithromycin capsules and solithromycin for injection, sponsored by Cempra Pharmaceuticals, Inc., respectively for the proposed indication of treatment of community-acquired bacterial pneumonia (CABP).
|Location:||tbd||Related News Links:||Not Available|